Micro-cap early-stage biotech Exicure, Inc.’s ($XCUR) shares rose sharply in premarket trading on Friday following a deal to acquire a cancer drug pipeline from a ...

CHICAGO, June 17, 2024--Exicure, Inc. (Nasdaq: XCUR, the "Company"), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor ...

An institutional investor recently bought a new position in Exicure stock. Geode Capital Management LLC purchased a new stake in shares of Exicure, Inc. (NASDAQ:XCUR – Free Report) during the ...

US biotech Exicure has raised $55 million in a public offering that has seen its shares elevated from over-the-counter (OTC) status to a full-blown Nasdaq listing. The cash injection will be used ...

Allergan hasn’t pressed pause on business development in the build-up to its $63 billion buyout by AbbVie, and has just agreed a deal with Exicure focusing on hair loss disorders. The alliance ...

(RTTNews) - Exicure, Inc. (XCUR), a biotechnology company, has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc., marking a major step in advancing its ...